secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2024-08-05T23:59:59+00:00
Accession:  0001048477-24-000125
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin Q2 revenue $712M (+20% YoY), GAAP EPS $0.55 (+90%), raises FY2024 guidance
--------------------------------------------------------------------------------

- VOXZOGO revenue $183.9M (+62% YoY); ~3,500 children on treatment across 44 countries.
- GAAP net income $107.2M (+91% YoY); Non-GAAP EPS $0.96 (+78% YoY) vs $0.54.
- FY2024 guidance raised: total revenue, Non-GAAP operating margin, Non-GAAP EPS all increased.
- ROCTAVIAN restructuring: focus on US, Germany, Italy; target $60M annual expenses by 2025; Q2 rev $7M.
- Discontinued BMN 293 (gene therapy for hypertrophic cardiomyopathy); BMN 351/349/333 on track.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000104847724000125/0001048477-24-000125-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000104847724000125/bmrn-20240805.htm
  HTML page:      https://secwatch.observer/filing/0001048477-24-000125

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer